Mathieu Bourdenx

Affiliations: 
Albert Einstein College of Medicine, New York, New York, United States 
Area:
Neuroscience, Neurodegeneration, Protein aggregation, Proteostasis, Aging, Lysosomes, Prion
Google:
"Mathieu Bourdenx"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Bourdenx M, Gavathiotis E, Cuervo AM. (2021) Chaperone-mediated autophagy: a gatekeeper of neuronal proteostasis. Autophagy. 1-3
Bourdenx M, Martín-Segura A, Scrivo A, et al. (2021) Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome. Cell
Caballero B, Bourdenx M, Luengo E, et al. (2021) Acetylated tau inhibits chaperone-mediated autophagy and promotes tau pathology propagation in mice. Nature Communications. 12: 2238
Bourdenx M, Nioche A, Dovero S, et al. (2020) Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates. Science Advances. 6: eaaz9165
Arotcarena ML, Dovero S, Prigent A, et al. (2020) Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. Brain : a Journal of Neurology
Arotcarena ML, Bourdenx M, Dutheil N, et al. (2019) Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies. Jci Insight. 4
Kirchner P, Bourdenx M, Madrigal-Matute J, et al. (2019) Proteome-wide analysis of chaperone-mediated autophagy targeting motifs. Plos Biology. 17: e3000301
Geier EG, Bourdenx M, Storm NJ, et al. (2018) Rare variants in the neuronal ceroid lipofuscinosis gene MFSD8 are candidate risk factors for frontotemporal dementia. Acta Neuropathologica
Scrivo A, Bourdenx M, Pampliega O, et al. (2018) Selective autophagy as a potential therapeutic target for neurodegenerative disorders. The Lancet. Neurology. 17: 802-815
Chansel-Debordeaux L, Bourdenx M, Dutheil N, et al. (2018) Systemic gene delivery by single-dose intracardiac administration of scAAV2/9 and scAAV2/rh10 variants in newborn rats. Human Gene Therapy Methods
See more...